BackKintara Therapeutics Overview

Kintara Therapeutics Minority Interest

Track Kintara Therapeutics's minority interest ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer average / median

Loading

Kintara Therapeutics Minority Interest History

Loading

Kintara Therapeutics vs. peers: Minority Interest Comparison

Loading

Kintara Therapeutics Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Kintara Therapeutics (KTRA) FAQ

Kintara Therapeutics's minority interest stands at $0 as of March 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Kintara Therapeutics reported $0 in minority interest versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in minority interest can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Kintara Therapeutics's minority interest evolved across reporting periods, while the comparison chart places KTRA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Materials, minority interest is commonly used to spot outliers. Kintara Therapeutics's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.